Walgreens Terminates Relationship with Theranos | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Walgreens Terminates Relationship with Theranos

June 13, 2016
by Heather Landi
| Reprints

As blood testing startup Theranos faces possible federal sanctions, Walgreens announced it has terminated its relationship with the company, and is closing operations at all Theranos Wellness Centers at its stores in Arizona.

Palo Alto, Calif.-based Theranos is a biomedical startup that has developed proprietary testing technology for blood testing. The company is facing increased scrutiny after voiding or correcting thousands of tests and faces possible federal sanctions for repeated failures at one of its labs.

Walgreens has partnered with Theranos for nearly three years, and its decision to sever ties follows an earlier announcement in January that it ceased Theranos laboratory testing services at its Palo Alto, Calif. location.

Walgreens will no longer offer Theranos services at any of its stores. The company said it will be working over the next several days to help transition customers.

Theranos has been under fire since a Wall Street Journal report last October suggested that the company’s inventions, including its Edison blood analyzer and its Nanotainer were only used on a small number of tests sold to patients.

As previously reported by Healthcare Informatics, back in October the U.S. Food and Drug Administration founds flaws in the process that Theranos used to validate its blood-testing products. In two inspection reports, the FDA referred to the company’s capillary tube nanotainer (CTN), a blood specimen collection device, as an “uncleared medical device.”

In January, The Centers for Medicare & Medicaid Services (CMS) sent a letter to blood analysis startup Theranos citing “deficient practices” at the company’s northern California lab which pose “immediate jeopardy to patient health and safety.”

The CMS letter dated January 25th, which was posted online, stated that the company had 10 days to provide “acceptable evidence of correction.” The document specifically cited problems with hematology, analytics systems, the laboratory director, the technical supervisor and laboratories performing high complexity testing that were found during an inspection late last year at the company’s Newark, California lab.

Theranos asked for an extension from CMS in February, which CMS granted.

At that time, Walgreens informed Theranos that it must immediately cease sending clinical laboratory tests provided through its Wellness Centers at Walgreens to the Theranos lab in Newark, Calif., which has been the subject of ongoing CMS review. At the same time, Walgreens also informed Theranos that tests collected at its Wellness Centers at Walgreens stores in Arizona must be sent only to Theranos’ certified lab in the Phoenix area or to an accredited third-party lab for analysis. No patient samples were to be sent to the Newark lab until all issues raised by CMS have been fully resolved.

More recently, in a letter dated March 18, CMS officials cited concerns that Theranos continued to fail compliance requirements and CMS proposed sanctions against the company, including revoking the license for its Newark, CA, lab and banning CEO Elizabeth Holmes from Theranos for at least two years.

With regard to Walgreens ending its business relationship with Theranos, Brad Fluegel, Walgreens senior vice president and chief health care commercial market development officer, said in a statement, “In light of the voiding of a number of test results, and as the Centers for Medicare and Medicaid Services (CMS) has rejected Theranos’ plan of correction and considers sanctions, we have carefully considered our relationship with Theranos and believe it is in our customers’ best interests to terminate our partnership.”

Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More

Topics

News

ONC Roundup: Senior Leadership Changes Spark Questions

The Office of the National Coordinator for Health IT (ONC) has continued to experience changes within its upper leadership, leading some folks to again ponder what the health IT agency’s role will be moving forward.

Media Report: Walmart Hires Former Humana Executive to Run Health Unit

Reigniting speculation that Walmart and insurer Humana are exploring ways to forge a closer partnership, Walmart Inc. has hired a Humana veteran to run its health care business, according to a report from Bloomberg.

Value-Based Care Shift Has Halted, Study Finds

A new study of 451 physicians and health plan executives suggests that progress toward value-based care has stalled. In fact, it may have even taken a step backward over the past year, the research revealed.

Study: EHRs Tied with Lower Hospital Mortality, But Only After Systems Have Matured

Over the past decade, there has been significant national investment in electronic health record (EHR) systems at U.S. hospitals, which was expected to result in improved quality and efficiency of care. However, evidence linking EHR adoption to better care is mixed, according to medical researchers.

Nursing Notes Can Help Predict ICU Survival, Study Finds

Researchers at the University of Waterloo in Ontario have found that sentiments in healthcare providers’ nursing notes can be good indicators of whether intensive care unit (ICU) patients will survive.

Health Catalyst Completes Acquisition of HIE Technology Company Medicity

Salt Lake City-based Health Catalyst, a data analytics company, has completed its acquisition of Medicity, a developer of health information exchange (HIE) technology, and the deal adds data exchange capabilities to Health Catalyst’s data, analytics and decision support solutions.